Are directors telling you it’s time to sell these popular growth stocks?

Should you get out of these two growth stars as founder directors dump £110m of shares?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It always gives me pause for thought when directors sell shares. Especially if the directors are also the founders, if their disposals are massive and if the share price has risen stratospherically high.

This has just happened with two popular growth stocks. Are the directors signalling that these stocks are now overvalued? And should you follow suit and cash in?

Running a fever

Fevertree (LSE: FEVR) has had a great run, its shares increasing more then tenfold since floating on AIM at 134p in 2014. Two weeks ago, the supplier of premium carbonated mixers for alcoholic spirits announced that co-founder and deputy chairman Charles Rolls intended to sell 2.5m shares. In the event, demand from institutional investors was such that he sold 4.5m, netting him a cool £73m at 1,625p a share.

However, he continues to hold almost 13m shares (an 11.2% stake in the business), worth over £200m. Furthermore, having sold shares in the IPO and another chunk last year at 635p, his disposals certainly haven’t foreshadowed a reversal in the price. I think Mr Rolls has simply done what most investors would do if they found that a single holding had come to represent a grossly disproportionate amount of their total wealth. Namely, take some profit.

Fizzy valuation

Fevertree’s share price has soared on the back of tremendous top- and bottom-line growth. The company reported a 49% increase in revenue and a 51% rise in earnings in its maiden results as a listed business. This accelerated to 71% and 87% the following year and to 73% and 101% last year.

The trailing price-to-earnings (P/E) ratio is over 70 at a current share price of 1,715p. Such a sky-high P/E would be acceptable if earnings were to continue increasing by a triple-digit percentage, but City analysts are forecasting growth to slow to mid-teens this year. In light of this rate of growth, the shares look too expensive to me on such a high earnings multiple.

Key director sales

Keywords Studios (LSE: KWS), which listed on AIM at 123p a share in 2013, is another company that’s delivered tremendous growth. This technical services provider to the video games industry also announced major share sales by founding directors two weeks ago.

Non-executive Giorgio Guastalla sold just shy of 4m shares and chief executive Andrew Day sold 500,000. Together they netted almost £37m at 820p a share. Again, though, they retain decent stakes in the business — 7.2% and 5.9%, respectively.

Possible problems and risks

Last year, Keywords increased its revenue by 67% and earnings by 61%, giving a trailing P/E of 45 at a current share price of 795p. But, as with Fevertree, earnings growth is forecast to moderate this year — to 25% in Keywords’ case.

The video tech firm’s valuation isn’t as rich as Fevertree’s but still looks on the pricey side to me, particularly as multiple acquisitions are a major part of its growth strategy. As Keywords acknowledges, this is a complex, costly and time-consuming process, involving a number of possible problems and risks. To compensate for this, I’d be looking for a lower valuation than that currently on offer.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Keywords Studios. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

10%+ dividend growth! 2 FTSE 250 shares tipped to turbocharge dividends

These FTSE 250 income shares look in great shape to grow their dividends by double-digit percentages, says our writer Royston…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

Would it be madness to buy this FTSE stock smashed by Donald Trump’s team picks?

Ben McPoland takes a look at one FTSE share inside his portfolio that has been battered lately due to a…

Read more »

Investing Articles

After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?

Harvey Jones has a big hole in his Stocks and Shares ISA that he is keen to fill. Should he…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

How’s the dividend forecast looking for Legal & General shares in 2025 and beyond?

As a shareholder, I like to keep track of the potential dividend returns I could make from my Legal &…

Read more »

artificial intelligence investing algorithms
Investing Articles

Could buying this stock with a $7bn market cap be like investing in Nvidia in 2010?

Where might the next Nvidia-type stock be lurking in today's market? Our writer takes a look at one candidate with…

Read more »

Investing Articles

Is GSK a bargain now the share price is near 1,333p?

Biopharma company GSK looks like a decent stock to consider for the long term, so is today's lower share price…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

Could December be a great month to buy UK shares?

Christopher Ruane sees some possible reasons to look for shares to buy in December -- but he'll be using the…

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

Sticking to FTSE shares, I’d still aim for a £1,000 monthly passive income like this!

By investing in blue-chip FTSE shares with proven business models, our writer hopes he can build sizeable passive income streams…

Read more »